Tabalumab (LY 2127399) is an anti-B-cell activating factor (BAFF) human monoclonal antibody designed for the treatment of autoimmune diseases and B cell malignancies.

A phase III clinical trial for rheumatoid arthritis was halted in Feb 2013.

[3] In September 2014, a second phase III trial focussing on treating systemic lupus erythematosus, was terminated early as the study failed to meet its primary endpoint.

[4] Immune activation: Dostarlimab Other: Ibalizumab Now dropped by Lilly due to lack of efficacy.

You can help Wikipedia by expanding it.This antineoplastic or immunomodulatory drug article is a stub.